Table 3. The effects of statin therapy on clinical outcomes.
| Total population | Propensity-matched population | |||
|---|---|---|---|---|
| *Composites of MACE | All-cause mortality | *Composites of MACE | All-cause mortality | |
| Kinds of statin | ||||
| Atorvastatin | 74 / 432 (17.1%) | 25 / 432 (5.8%) | 29 / 145 (20.0%) | 6 / 145 (4.1%) |
| Rosuvastatin | 26 / 193 (13.5%) | 12 / 193 (6.2%) | 9 / 63 (14.3%) | 5 / 63 (7.9%) |
| Pitavastatin | 12 / 68 (17.6%) | 2 / 68 (2.9%) | 5 / 28 (17.9%) | 0 / 28 (0%) |
| Simvastatin | 9 / 41 (22.0%) | 2 / 41 (4.9%) | 1 / 13 (7.7%) | 0 / 13 (0%) |
| Pravastatin | 3 / 17 (17.6%) | 2 / 17 (11.8%) | 2 / 7 (28.6%) | 2 / 7 (28.6%) |
| Fluvastatin | 1 / 5 (20.0%) | 0 / 5 (0%) | - | - |
| Intensities of statin | ||||
| Low | 2 / 11 (18.2%) | 1 / 11 (9.1%) | 1/6 (16.7%) | 1/3 (33.3%) |
| Moderate | 102 / 615 (16.6%) | 33 / 615 (5.4%) | 21/222 (9.5%) | 8/213 (3.8%) |
| High | 21 / 130 (16.2%) | 9 / 130 (6.9%) | 5/62 (8.1%) | 4/40 (10.0%) |
*Composed of all-cause mortality, myocardial infarction (MI), any repeated revascularization. MACE, major adverse cardiovascular event